| Outline of Final Research Achievements |
In castration-resistant prostate cancer, 80% of these cases proceed to bone metastasis with skeletal related events, resulting in reduced quality of life. To recover from this condition, alpha-emitting radionuclide therapy (223Ra) is widely used to combat bone metastasis from CRPC. However, numerous variances in both therapeutic effects and side effects have been reported. We found that phosphatidylcholine (PC) is a predictive biomarker for 223Ra treatment in these patients.In patient analysis, serum bone microemvironment markers, such as BAP and NTx, showed an alteration of individual variety. However, an up-regulated PC concentration of serum in good outcome was observed than poor outcome. PC that was detected in cell line model showed a similar trend in comparison to a clinical serum assay. These results suggest that PC production in prostate cancer cell exposed to ionizing radiation shows a dose-dependent mechanism associated with cell damage and cell death.
|
